Developing Drugs Faster
Wuxi Biologics’ R&D platform has been critical in the manufacture of vaccines and therapeutic antibodies against COVID-19.
Wuxi Biologics provides laboratory and manufacturing services for pharmaceutical and biotech companies to help these companies discover, develop, and manufacture biologic drugs faster, more cost-effectively, and more efficiently. The Shanghai-based company’s open services and technology platform speeds the development of new drugs by making it possible for more researchers, hospitals, and entrepreneurs to develop drugs. Rapid and accurate drug development saves more patients’ lives.
Wuxi’s efficiency, flexibility, and speed of execution have been critical in the battle against the global coronavirus pandemic. The company has filed applications for clinical trials of seven investigational new drugs with antibodies that can neutralize COVID-19, in timelines of three to five months, global record speed. The company mobilized a team of more than 1,000 scientists to help global partners find potential treatments. It initiated projects on the Chinese New Year and leveraged its platform to enable customers to work from home during the pandemic to speed drug delivery. As it did this, Wuxi also reduced the standard investigational new drug timelines from 15 months to 12 months. It continues to serve as a partner for multinational and Chinese biopharmaceutical companies to discover, develop, and manufacture vaccines and therapeutic antibodies against COVID-19. And it has positioned itself to aid companies on the front lines of developing personalized medicine and biologic drugs.
To build an open-access platform with extremely comprehensive capabilities and technologies to enable drug research and development (R&D) and manufacturing, Wuxi prioritized intellectual property protection, product and service quality, corporate governance, compliance and business ethics, and industry development and supply. Wuxi was selected as a “Most Honored Company” by Institutional Investor in 2020, based on the strength of its corporate governance and investor relations management. As part of its corporate social responsibility model, Wuxi continuously improves both the capacity and capabilities of its open-access platform to enable more innovators and entrepreneurs to participate in each step of drug R&D, and to empower more research institutions, scientists, hospitals, and doctors to turn their ideas into products, thereby benefiting more patients.
The company is also committed to environmental principles. As it developed its platform, Wuxi studied pollution sources, water resource utilization, energy use, mitigation and adaption of climate change, green chemistry, community and public welfare, and responsible procurement, to help ensure that it operates in the most environmentally sound way. Wuxi has embraced green manufacturing and uses sustainable supply chain management practices, partnering with key stakeholders, such as suppliers, on implementing best practices. It has integrated these and other corporate social responsibility goals into the responsibilities of departments—such as purchasing—throughout the company to ensure continuous progress and improvement.
Wuxi recently expanded its presence in Europe by acquiring a manufacturing facility in Germany and in the United States by expanding laboratories, as well as manufacturing and clinical facilities. Wuxi has said it will continue to be an enabler of the healthcare industry around the globe in years to come. In doing so, the company plans to further its vision that “every drug can be made and every disease can be treated,” all while supporting relevant sustainable development goals for the pharmaceutical and healthcare industries, and for the environment and community.
Sustainable Development Goals
The Sands Capital six investment criteria tend to lead us to businesses that are innovators or vital facilitators of change in industries undergoing significant transformation. Wuxi is one of many portfolio businesses that create impact by addressing at least one major social or environmental challenge identified by the United Nations Sustainable Development Goals (SDGs). The SDGs to which Wuxi contributes include SDG 3, Good Health and Well Being; SDG 9, Industry Innovation and Infrastructure, SDG 11, Sustainable Cities and Communities; SDG 12, Responsible Consumption and Production; and SDG 13, Climate Action.
The business profiled was selected based on its reported alignment with one or more U.N. Sustainable Development Goals. The views expressed are the opinion of Sands Capital Management and are not intended as a forecast, a guarantee of future results, investment recommendations, or an offer to buy or sell any securities. The views expressed were current as of the date indicated and are subject to change. This material may contain forward-looking statements, which are subject to uncertainty and contingencies outside of Sands Capital’s control. Readers should not place undue reliance upon these forward-looking statements. There is no guarantee that Sands Capital will meet its stated goals. Past performance is not indicative of future results. A company’s fundamentals or earnings growth is no guarantee that its share price will increase. Forward earnings projections are not predictors of stock price or investment performance, and do not represent past performance. The specific securities identified and described do not represent all the securities purchased, sold, or recommended for advisory clients. There is no assurance that any security will continue to be owned by Sands Capital Management. You should not assume that any investment is or will be profitable. All company logos and website images are used for illustrative purposes only and were obtained directly from the company websites. Company logos and website images are trademarks or registered trademarks of their respective owners and use of a logo does not imply any connection between Sands Capital and the company. GIPS® Reports and additional disclosures for the related composites may be found in the Sands Capital GIPS Report.